Results 91 to 100 of about 6,010 (179)

Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review

Canadian Respiratory Journal, 2018
Objectives. Although many studies have reported on the cost-effectiveness of bosentan for treating pulmonary arterial hypertension (PAH), a systematic review of economic evaluations of bosentan is currently lacking.
Ruxu You, Xinyu Qian, Weijing Tang, Tian Xie, Fang Zeng, Jun Chen, Yu Zhang, Jinyu Liu   +7 more
doaj   +1 more source

Epoprostenol Therapy for Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is characterized by elevation of pulmonary artery pressure caused by pulmonary vasoconstriction and vascular remodeling, which leads to right heart failure and death.
Nakamura, Kazufumi, Matsubara, Hiromi, Sarashina, Toshihiro, Ejiri, Kentaro, Ito, Hiroshi, Ogawa, Aiko, Akagi, Satoshi   +6 more
core  

Use of intravenous epoprostenol as a treatment for the digital vasculopathy associated with the scleroderma spectrum of diseases

, 2017
Introduction Intravenous prostanoid therapy is recommended for severe systemic sclerosis-related digital vasculopathy. The evidence supporting this recommendation is limited.
Robert W. Simms, Shing T. Law, Harrison W. Farber   +2 more
core   +1 more source

Different effects of epoprostenol on ischemia-induced ventricular arrhythmias in dogs.

, 1990
In 60 randomized dogs the effects of epoprostenol infusion (100 ng/kg/min) on ischemia-induced premature ventricular contractions (PVCs), ventricular tachycardia (VT), ventricular flutters and ventricular fibrillation were studied.
F. Langlet, A. A. Dawodu, F. Monti, PUDDU, Paolo Emilio, SCHIARITI, Michele Salvatore Maria, J. C. Guillen, A. Reale, M. Lanti   +7 more
core  

Inhaled Epoprostenol for an Intermediate-High-Risk Pulmonary Embolism With an Aortic Intramural Hematoma

Annals of Internal Medicine: Clinical Cases
Intermediate-high-risk pulmonary embolism (PE) is typically treated with anticoagulation. However, reperfusion therapy may be contraindicated when bleeding risk is high. We describe a 72-year-old man with a type B aortic intramural hematoma who presented
James E. Carlton, Iuliia Kovalenko
doaj   +1 more source

Use of Inhaled Epoprostenol in Patients with H1N1 Influenza-Associated Acute Respiratory Distress Syndrome: A Case Series

, 2011
Objective: To report a series of patients with confirmed novel influenza A (H1N1) and refractory hypoxemia secondary to acute respiratory distress syndrome (ARDS) treated with inhaled epoprostenol.
Christopher F Burke, Barbara E Faircloth, Tina M Dudney, Amit Dhingra, James C McMillen   +4 more
core   +1 more source

Severe bronchospasm and acute respiratory failure associated with inhaled prostacyclin therapy

Pulmonary Circulation
Prostacyclin therapy is a mainstay of the management of pulmonary arterial hypertension (PAH). Inhaled prostacyclins present safe and effective options for the management of PAH that limit systemic side effects.
Donna Steinbacher, Brian Murray, Thomas Devlin, Shannon S. Carson, H. James Ford   +4 more
doaj   +1 more source

Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension

, 1997
The association of pulmonary hypertension with portal hypertension, also called portopulmonary hypertension (PPHTN), is a known complication of chronic liver disease. Previously, the presence of PPHTN was considered to be a contraindication to orthotopic
Kuo, Paul C., Johnson, Lynt B., Bartlett, Stephen T., Plotkin, Jeffrey S., Rubin, Lewis J., Howell, Charles D.   +5 more
core   +1 more source

Inhaled Epoprostenol During One-Lung Ventilation

, 2010
We used inhaled epoprostenol (with intravenous phenylephrine) during one-lung ventilation to improve oxygenation in a patient with severe interstitial lung disease undergoing video-assisted thoracoscopic surgery.
Connelly, Neil, MD, Ganim, Rose, MD, Raghunathan, Karthik, MD, Hochheiser, Gary, MD, Robbins, Larry, MD   +4 more
core   +1 more source

Intrapulmonary shunting in primary pulmonary hypertension - An observation in two patients treated with epoprostenol sodium

, 1998
Continuous intravenous infusion of epoprostenol sodium in selected patients with primary pulmonary hypertension improves symptoms and survival. This report describes two patients with primary pulmonary hypertension treated with epoprostenol in whom ...
McGiffin, DC, Pinkard, NB, Benza, RL, Fan, P, McGoon, MD, Castro, PF, Bourge, RC   +6 more
core